Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
467
datasets available to search
ShareScore release 0.9.0
Dataset results
467 results for “Trial Data”
Data set from Ciconte G, Santinelli V, Vicedomini G, Borrelli V, Monasky MM, Micaglio E, Giannelli L, Negro G, Giordano F, Mecarocci V, Mazza BC, Locati E, Anastasia L, Calovic Z, Pappone C. Non-invasive assessment of the arrhythmogenic substrate in Brugada syndrome using signal-averaged electrocardiogram: clinical implications from a prospective clinical trial. Europace. 2019 Dec 1;21(12):1900-1910. doi: 10.1093/europace/euz295. PMID: 31647530.
<p>Data set from Ciconte G, Santinelli V, Vicedomini G, Borrelli V, Monasky MM, Micaglio E, Giannelli L, Negro G, Giordano F, Mecarocci V, Mazza BC, Locati E, Anastasia L, Calovic Z, Pappone C. Non-invasive assessment of the arrhythmogenic substrate in Brugada syndrome using signal-averaged electrocardiogram: clinical implications from a prospective clinical trial. Europace. 2019 Dec 1;21(12):1900-1910. doi: 10.1093/europace/euz295. PMID: 31647530.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Aims: </strong> Brugada syndrome (BrS) represents a major cause of sudden cardiac death in young individuals. The risk stratification to forecast future life-threatening events is still controversial. Non-invasive assessment of late potentials (LPs) has been proposed as a risk stratification tool. However, their nature in BrS is still undetermined. The purpose of this study is to assess the electrophysiological determinants of non-invasive LPs.</p> <p><strong>Methods and results: </strong> Two hundred and fifty consecutive patients with (Group 1, n = 96) and without (Group 2, n = 154) BrS-related symptoms were prospectively enrolled in the registry. Signal-averaged electrocardiogram (SAECG) was performed in all subjects before undergoing epicardial mapping. Group 1 patients exhibited larger arrhythmogenic substrates (AS; 5.8 ± 2.8 vs. 2.6 ± 2.1 cm2, P < 0.001) with more delayed potentials (220.4 ± 46.0 vs. 186.7 ± 42.3 ms, P < 0.001). Late potentials were present in 82/96 (85.4%) Group 1 and in 31/154 (20.1%) Group 2 individuals (P < 0.001). Patients exhibiting LPs had more frequently a spontaneous Type 1 pattern (30.1% vs. 10.9%, P < 0.001), SCN5A mutation (34.5% vs. 21.2%, P = 0.02), and exhibited a larger AS with longer potentials (5.8 ± 2.7 vs. 2.2 ± 1.7 cm2; 231.2 ± 37.3 vs. 213.8 ± 39.0 ms; P < 0.001, respectively). Arrhythmogenic substrate dimension was the strongest predictor of the presence of LPs (odds ratio 1.9; P < 0.001). An AS area of at least 3.5 cm2 identified patients with LPs (area under the curve 0.88, 95% confidence interval 0.843-0.931; P < 0.001) with a sensitivity of 86%, specificity 88%, positive predictive value 85%, and negative predictive value 89%.</p> <p><strong>Conclusion: </strong> The results of this study support the role of the epicardial AS as an electrophysiological determinant of non-invasive LPs, which may serve as a tool in the non-invasive assessment of the BrS substrate, as SAECG-LPs could be considered an expression of the abnormal epicardial electrical activity.</p> <p>ClinicalTrials.gov number (<a href="http://clinicaltrials.gov/show/NCT02641431">NCT02641431</a>; <a href="http://clinicaltrials.gov/show/NCT03106701">NCT03106701</a>).</p> <p> </p>
Tissue Cytokine Data from Virotherapy Trial and concomitant Explant Model testing
<p>Cytokine Data from serial biopsies from a virotherapy trial and Cytokine Data from systematic Explant Model testing with the similar treatment regimen.</p>
Deidentified Data for Clinical Trial and Clinical Evidence
<p>The data are the clinical evidence for the existence of SARS-CoV-2 "vaccination" poisoning and PCR tests cannot test "vaccinated" SARS-CoV-2 viral infections. The hospital system in PRC changed the lower threshold of basophil indicators in blood tests to hide the clinical evidence indicators from the patients. The monitoring photos are from the clinical trial for medicine-induced hemodialysis. The one-week clinical trial has detached protein allergic reactions from the platelet with mild process, increased the patient's basophils health even though the eosinophil increased. It evidences the Spike 2 protein's immune attacks.</p>
Data related to article EFFICACY OF MINDFULNESS ADDED TO TREATMENT AS USUAL IN PATIENTS WITH CHRONIC MIGRAINE AND MEDICATION OVERUSE HEADACHE: A PHASE-III SINGLE-BLIND RANDOMIZED-CONTROLLED TRIAL (THE MIND-CM STUDY) - submitted
<p>DATA ON PATIENTS INCLUDED IN THE MIND-CM STUDY. TWO ARMS (TAU AND TAU+MIND), AND FOUR EVALUATIONS: BASELINE, 3-MONTHS, 6-MONTHS AND 12-MONTS FOLLOW-UP.</p>
Dataset related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial"</p><p>Abstract</p><p><strong>Aims: </strong>We report the mature toxicity data of a phase II non-randomized trial on the use of SBRT for lung and liver oligometastases.</p><p><strong>Methods: </strong>Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions. Inclusion criteria were: age > 18 years, ECOG 0-2, diagnosis of breast cancer, less than five lung/liver lesions (with a maximum diameter <5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. Various dose-fractionation schedules were used. Then, a 4D-CT scan and FDG-CTPET were acquired for simulation and fused for target definition.</p><p><strong>Results: </strong>From 2015 to 2021, 64 patients and a total of 90 lesions were irradiated. Treatment was well tolerated, with no G 3-4 toxicities. No grade ≥3 toxicities were registered and the coprimary endpoint of the study was met. Median follow-up was 19.4 months (range 2.6-73.1).</p><p><strong>Conclusions: </strong>The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.</p>
Expression data from 36 KRAS-mutant lung adenocarcinomas from the BATTLE-2 clinical trial.
GEO Series GSE61913. Homo sapiens. 36 samples. Type: Expression profiling by array.
Data from; Concentration-Dependent Impact of Green Tea Catechin Gargling on Acute Upper Respiratory Tract Infections: An Exploratory Randomized Controlled Trial
<p>We conducted an open-label randomized study (UMIN000045060). The target population consisted of 209 students from the University of Shizuoka and Meiji University, who were randomly assigned to high-catechin (70 participants, approximate catechin concentration: 76.4 mg/dL), low-catechin (69 participants, approximate catechin concentration: 30.8 mg/dL), and a control water gargling (70 participants, catechin concentration: 0 mg/dL) groups. All participants gargled water or GT thrice daily for 12 weeks between December 2021 and February 2022. The symptoms experienced by participants who developed URTI during the study period were recorded on a survey form. The primary endpoint of URTI occurred in 6 (9.1%), 7 (10.8%), and 11 (15.7%) participants in the high-catechin, low-catechin, and water groups, respectively (Fisher's exact test for the overall group: <em>p</em>=0.482). Cox proportional hazards analysis, using background factors and prevention status as covariates, revealed a hazard ratio of 0.57 (95% CI: 0.21–1.55, <em>p</em>=0.261) for the high-catechin vs. water group and 0.54 (95% CI: 0.20–1.50, <em>p</em>=0.341) for the low-catechin vs. water group.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.